Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-02-25 DOI:10.1080/14737140.2025.2471010

Onur Baş, Mert Tokatlı, Mehmet Şavklıyıldız, Yiğit Yazarkan, Naciye Guduk, Can Kılınç, Latif Karahan, Taha Koray Şahin, Deniz Can Guven, Sercan Aksoy

{"title":"Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors.","authors":"Onur Baş, Mert Tokatlı, Mehmet Şavklıyıldız, Yiğit Yazarkan, Naciye Guduk, Can Kılınç, Latif Karahan, Taha Koray Şahin, Deniz Can Guven, Sercan Aksoy","doi":"10.1080/14737140.2025.2471010","DOIUrl":null,"url":null,"abstract":"Background: The objective of this study is to evaluate the correlation between survival outcomes and the modified cachexia index (mCXI) in patients with metastatic breast cancer who have been treated with cyclin-dependent kinase (CDK) 4/6 inhibitors.Methods: This study was conducted on patients with metastatic breast cancer who received CDK 4/6 inhibitors (either Palbociclib or Ribociclib) between January 2020 and November 2024.Results: 240 patients were included. A total of 236 patients (98.3%) were female. Median age was 57 (IQR: 48-66 years). The median follow-up period from the initiation of CDK 4/6 inhibitors to the last control was 20 months. One hundred eighty-four patients (76.7%) received ribociclib, while 56 (23.3%) received palbociclib. At diagnosis, 179 patients (74.6%) had metastatic disease. Patients are classified as modified cachexia index-low (mCXI-Low) and mCXI-High according to the receiver operating characteristic (ROC) analysis results for overall survival (OS) prediction [AUC: 0,654 p:<0,001 Cut-off value = 93.5]. Following multivariate analysis, both progression-free survival [HR: 1.50 (95% CI 1.07-2.12), p = 0.02] and overall survival [HR: 3.22 (95% CI 1.90-5.46), p < 0.001] were found to be significantly associated with mCXI.Conclusion: mCXI is associated with overall survival in metastatic breast cancer patients who are treated with CDK 4-6 inhibitors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-5"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2471010","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The objective of this study is to evaluate the correlation between survival outcomes and the modified cachexia index (mCXI) in patients with metastatic breast cancer who have been treated with cyclin-dependent kinase (CDK) 4/6 inhibitors.

Methods: This study was conducted on patients with metastatic breast cancer who received CDK 4/6 inhibitors (either Palbociclib or Ribociclib) between January 2020 and November 2024.

Results: 240 patients were included. A total of 236 patients (98.3%) were female. Median age was 57 (IQR: 48-66 years). The median follow-up period from the initiation of CDK 4/6 inhibitors to the last control was 20 months. One hundred eighty-four patients (76.7%) received ribociclib, while 56 (23.3%) received palbociclib. At diagnosis, 179 patients (74.6%) had metastatic disease. Patients are classified as modified cachexia index-low (mCXI-Low) and mCXI-High according to the receiver operating characteristic (ROC) analysis results for overall survival (OS) prediction [AUC: 0,654 p:<0,001 Cut-off value = 93.5]. Following multivariate analysis, both progression-free survival [HR: 1.50 (95% CI 1.07-2.12), p = 0.02] and overall survival [HR: 3.22 (95% CI 1.90-5.46), p < 0.001] were found to be significantly associated with mCXI.

Conclusion: mCXI is associated with overall survival in metastatic breast cancer patients who are treated with CDK 4-6 inhibitors.

查看原文本刊更多论文

研究背景本研究旨在评估接受细胞周期蛋白依赖性激酶（CDK）4/6抑制剂治疗的转移性乳腺癌患者的生存结果与改良恶病质指数（mCXI）之间的相关性：研究对象为2020年1月至2024年11月期间接受CDK 4/6抑制剂（Palbociclib或Ribociclib）治疗的转移性乳腺癌患者。共有 236 名患者（98.3%）为女性。中位年龄为 57 岁（IQR：48-66 岁）。从开始使用 CDK 4/6 抑制剂到最后一次对照的中位随访时间为 20 个月。184名患者（76.7%）接受了ribociclib治疗，56名患者（23.3%）接受了palbociclib治疗。确诊时，179 名患者（74.6%）患有转移性疾病。根据总生存期（OS）预测[（AUC：0,654 p：p = 0.02]和总生存期[HR：3.22（95% CI 1.90-5.46），p 结论：在接受 CDK 4-6 抑制剂治疗的转移性乳腺癌患者中，mCXI 与总生存期相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.